Full text is available at the source.
Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives
Tirzepatide’s effects on fatty liver disease linked to metabolism: results from phase II trials and future outlook
AI simplified
Abstract
Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.
- Tirzepatide is associated with improved glucose metabolism and reduced food intake.
- In the SYNERGY-NASH phase 2 study, a higher percentage of patients treated with tirzepatide experienced MASH resolution compared to those receiving placebo.
- More patients in the tirzepatide group achieved a 1-stage or greater improvement in fibrosis without worsening MASH, though this was not the primary focus of the study.
- Noninvasive biomarkers of fibrosis did not show significant improvement in either treatment group.
AI simplified